| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total revenues | 141 | 70,570 | 75 | 72 |
| Research and development (including related party expenses of and 4,528 during the three and six months ended june30, 2025, respectively, and 2,551 and 3,212 during the three and six months ended june30, 2024, respectively)-Paragon Therapeutics | NaN | NaN | 0 | NaN |
| Research and development | 77,631 | 86,261 | 86,626 | 76,835 |
| General and administrative | NaN | 24,322 | 20,216 | 17,103 |
| Selling, general and administrative | 38,679 | NaN | NaN | NaN |
| Total operating expenses | 116,310 | 110,583 | 106,842 | 93,938 |
| Loss from operations | -116,169 | -40,013 | -106,767 | -93,866 |
| Interest income | 7,872 | 5,521 | NaN | NaN |
| Interest expense | 3,462 | 560 | 514 | 586 |
| Change in fair value of derivative liability | 7,530 | NaN | NaN | NaN |
| Interest and other income | NaN | NaN | 6,546 | 7,540 |
| Other expense, net | -672 | 453 | NaN | NaN |
| Total other income, net | 11,268 | 5,414 | 6,032 | 6,954 |
| Net loss | -104,901 | -34,599 | -100,735 | -86,912 |
| Unrealized gain (loss) on available-for-sale securities | -1,008 | 294 | -176 | NaN |
| Change in unrealized (loss) gain on investments | NaN | NaN | NaN | 255 |
| Change in cumulative translation adjustment | 3 | NaN | NaN | NaN |
| Total other comprehensive income (loss) | -1,005 | 294 | -176 | 255 |
| Comprehensive loss | -105,906 | -34,305 | -100,911 | -86,657 |
| Basic EPS | -0.9 | -0.34 | NaN | -0.87 |
| Diluted EPS | -0.9 | -0.34 | NaN | -0.87 |
| Basic Average Shares | 102,211,657 | 81,784,499 | NaN | 81,344,134 |
| Diluted Average Shares | 102,211,657 | 81,784,499 | NaN | 81,344,134 |
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)